TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27163418

Group type: EXPERIMENTAL
Intervention: Positive-end expiratory pressure of 5 cm H2O (Group A, n=32)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Positive-end expiratory pressure of 8 cm H2O (Group B, n=26)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Positive-end expiratory pressure of 10 cm H2O (Group C, n=20)
Number of subjects: 78
Study: 23703602

Group type: EXPERIMENTAL
Intervention: 5 times/week abdominal meridian massage with aroma oils (AMMAO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3 times/week abdominal meridian massage with aroma oils (AMMAO)
Number of subjects: 33
Study: 21296544

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (Vicryl Plus)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Conventional Vicryl sutures
Number of subjects: 241
Study: 19861543

Group type: EXPERIMENTAL
Intervention: 3.0-g bovine lactoferrin (bLF) daily for 12 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 1.5-g bovine lactoferrin (bLF) daily for 12 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 16518959

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) in combination with lopinavir/ritonavir, efavirenz, lamivudine, and tenofovir
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no enfuvirtide) with the same four-drug regimen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no enfuvirtide)
Number of subjects: 16
Study: 15233288

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node identification using lymphoscintigraphy and handheld gamma probe
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Histopathology of sentinel lymph nodes
Number of subjects: 11
Study: 11506518

Group type: EXPERIMENTAL
Intervention: Homologous blood transfusion
Number of subjects: 128

Group type: COMPARATOR
Intervention: No transfusion (Control)
Number of subjects: 128
Study: 9407455

Group type: EXPERIMENTAL
Intervention: AST-120 (6 g/day) concurrent with low protein diet (LPD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Low protein diet (LPD) alone
Number of subjects: 26
Study: 8508355

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine (VCR)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Induction therapy without vincristine (VCR)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 12 courses of maintenance‐intensification therapy
Number of subjects: 252

Group type: COMPARATOR
Intervention: 4 courses of maintenance‐intensification therapy
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Overall results for CR
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 252
Study: 3479420

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally twice daily for 14 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg orally twice daily for 14 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (placebo) not explicitly mentioned
Number of subjects: 26
Study: 29986120

Group type: EXPERIMENTAL
Intervention: My Guide (Smartphone application)
Number of subjects: 25
Study: 28061361

Group type: EXPERIMENTAL
Intervention: Retroauricular (RA) approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional transcervical approach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 30
Study: 25616042

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) at doses of 200-400 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) at doses of 600-800 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 24342552

Group type: COMPARATOR
Intervention: OT only
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MP + OT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: OT only and MP + OT
Number of subjects: 18
Study: 22119451

Group type: EXPERIMENTAL
Intervention: Emotion dysregulation
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Distress tolerance
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Interaction between emotion dysregulation and distress tolerance
Number of subjects: 172
Study: 19110359

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 17295082

Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) plus antiplatelet therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 60
Study: 15170163

Group type: EXPERIMENTAL
Intervention: Blood stem cells (BSC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sequential skin biopsies
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Affected skin immunohistochemistry
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Normal skin biopsies before GVHD outbreak
Number of subjects: 61
Study: 11585352

Group type: EXPERIMENTAL
Intervention: Continuous ibandronate 2.5 mg daily (n = 81)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intermittent ibandronate 20 mg every other day for the first 24 days (n = 78)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Continuous ibandronate (after crossover, n = 37)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intermittent ibandronate (after crossover, n = 35)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both treatment groups (continuous and intermittent)
Number of subjects: 240
Study: 10447226

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS)
Number of subjects: 157
Study: 7796795

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2496789

Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg orally every four hours for 21 days
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 723760

Group type: EXPERIMENTAL
Intervention: Clofibate (2 X 1 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Bezafibrate (3 X 150 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 29725824

Group type: EXPERIMENTAL
Intervention: Intervention spread with 2.0 g/day plant sterols and 1.0 g/day EPA+DHA from fish oil
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 260
Study: 28529330

Group type: EXPERIMENTAL
Intervention: High MC-SFA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low MC-SFA
Number of subjects: 12
Study: 25123295

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) with prednisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone alone (placebo)
Number of subjects: 20
Study: 25127179

Group type: EXPERIMENTAL
Intervention: iACT (Internet-based ACT program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face ACT treatment
Number of subjects: 0
Study: 22376210

Group type: EXPERIMENTAL
Intervention: Test gel (anesthetic gel)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test gel
Number of subjects: 30
Study: 18636272

Group type: EXPERIMENTAL
Intervention: Emotional words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High state anxiety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral words
Number of subjects: 0
Study: 17495015

Group type: EXPERIMENTAL
Intervention: Adapted-dose azathioprine therapy (adjusted to maintain 6-TGN concentrations between 250 and 400 pmol/8 x 10(8) erythrocytes)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard-dose azathioprine therapy (2.5 mg/kg/day)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Adapted-dose azathioprine therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard-dose azathioprine therapy
Number of subjects: 71
Study: 15121553

Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supracervical Hysterectomy (SCH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Baseline body mass index ≥ 35 kg/m²
Number of subjects: 120

Group type: COMPARATOR
Intervention: Baseline body mass index < 35 kg/m²
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heavy bleeding
Number of subjects: 120

Group type: COMPARATOR
Intervention: No heavy bleeding
Number of subjects: 120
Study: 11231772

Group type: EXPERIMENTAL
Intervention: Timolol and fluorometholone (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PV and fluorometholone (group D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPV and fluorometholone (group F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Groups receiving diclofenac (groups A, C, E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol (0.5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PV or NPV (control groups)
Number of subjects: 0
Study: 9754465

Group type: EXPERIMENTAL
Intervention: Acetate hemodialysis (AHD)
Number of subjects: 33
Study: 8313125

Group type: EXPERIMENTAL
Intervention: Peripheral IVN system with fine-bore silicone catheter and lipid-based nutrient solutions
Number of subjects: 46

Group type: COMPARATOR
Intervention: Central IVN system with conventional glucose-based nutrient regimen and single-lumen central venous catheter
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of complication-free system function over time between peripheral and central IVN
Number of subjects: 46
Study: 2478330

Group type: EXPERIMENTAL
Intervention: Antithrombin III/low-dose heparin (ATIII/LDH) regimen (3000 units loading dose followed by 2000 units daily and 5000 units of LDH twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-molecular-weight dextran (LMWD) (10 ml/kg x 12 hours loading dose followed by 7 ml/kg x 24 hours maintenance dose)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (ATIII/LDH and LMWD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ATIII/LDH group
Number of subjects: 42
Study: 786311

Group type: EXPERIMENTAL
Intervention: WA 335 (3 X 1 mg/die)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Amitriptyline (3 X 50 mg/die)
Number of subjects: 116
Study: 29790196

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 57
Study: 28235726

Group type: EXPERIMENTAL
Intervention: CCRT plus AC (adjuvant cisplatin 80 mg/m2 and fluorouracil 800 mg/m2/d for 120 h every 4 weeks for three cycles)
Number of subjects: 508

Group type: COMPARATOR
Intervention: CCRT only
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: CCRT plus AC
Number of subjects: 508
Study: 25920942

Group type: EXPERIMENTAL
Intervention: Stroke support service (outreach work, informational events, training sessions, online portal, written patient information)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Stroke support service
Number of subjects: 265

Group type: COMPARATOR
Intervention: Optimized standard care (written patient information)
Number of subjects: 265
Study: 23228500

Group type: EXPERIMENTAL
Intervention: 9.5% H₂O₂ high‐adhesion whitening strip for 2h, once a day, for 8 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10% H₂O₂ whitening strip for 30 min, once a day, for 8 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 9.5% H₂O₂ high‐adhesion whitening strip
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10% H₂O₂ whitening strip
Number of subjects: 29
Study: 22012289

Group type: EXPERIMENTAL
Intervention: II and IH nerve block with 10 mL of 0.75% ropivacaine and surgical wound infiltration with 10 mL of 0.75% ropivacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Spinal anesthesia with 15 mg hyperbaric 0.5% bupivacaine (Control Group)
Number of subjects: 34
Study: 19198920

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 50
Study: 17403400

Group type: EXPERIMENTAL
Intervention: laxative (magnesium oxide + disodium phosphate)
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study: 15576019

Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IU of albumin-free recombinant streptokinase (rSK) in a one-hour intravenous infusion
Number of subjects: 25
Study: 11171896

Group type: EXPERIMENTAL
Intervention: IVIg + prednisone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo + prednisone
Number of subjects: 36
Study: 9609895

Group type: EXPERIMENTAL
Intervention: Perflenapent emulsion (0.05 mL/kg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 7809568

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3406619

Group type: EXPERIMENTAL
Intervention: Resistive training with non-linear resistance (Group 1, n = 3)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo training (Group 2, n = 2)
Number of subjects: 5
Study: 31123001

Group type: EXPERIMENTAL
Intervention: Individualised antiplatelet therapy based on pharmacogenetic information and clinical features (pharmacogenetic group)
Number of subjects: 2382

Group type: COMPARATOR
Intervention: Standard care based only on clinical features (standard group)
Number of subjects: 2382
Study: 29970404

Group type: EXPERIMENTAL
Intervention: PSA-DBS
Number of subjects: 13

Group type: COMPARATOR
Intervention: VIM-DBS
Number of subjects: 13
Study: 27573427

Group type: EXPERIMENTAL
Intervention: Good QLQ‐C30 PF (score > 66.7%)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Poor QLQ‐C30 PF (score ≤ 66.7%)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Good QLQ‐C30 PF
Number of subjects: 300

Group type: COMPARATOR
Intervention: WHO PS
Number of subjects: 300
Study: 24618231

Group type: EXPERIMENTAL
Intervention: Concentrated ambient coarse particles (CAP; 76.2 ± 51.5 μg/m(3))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 32
Study: 22795976

Group type: EXPERIMENTAL
Intervention: ketorolac 0.5%
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Number of subjects: 162

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: ketorolac 0.5% and nepafenac 0.1%
Number of subjects: 162
Study: 19093773

Group type: EXPERIMENTAL
Intervention: Autologous tumor cell-derived vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic tumor cell-derived vaccines
Number of subjects: 0
Study: 18192950

Group type: EXPERIMENTAL
Intervention: Vasoactive agents (inotropes and pressor agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 0
Study: 15167885

Group type: EXPERIMENTAL
Intervention: Early Total Parenteral Nutrition (ETPN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Late Total Parenteral Nutrition (LTPN)
Number of subjects: 32
Study: 11669169

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) 3 mg/kg/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 2,000 mg/day
Number of subjects: 99
Study: 9676479

Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control feedback
Number of subjects: 8
Study: 7988307

Group type: EXPERIMENTAL
Intervention: Improved glycemic control in poorly controlled NIDDM patients (54 patients)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: NIDDM patients with HbA1c < 6.0% (62 patients)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: NIDDM patients with HbA1c between 6.0 and 8.0% (75 patients)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: NIDDM patients with HbA1c >= 8.0% (73 patients)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control subjects (46 subjects)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Improved glycemic control
Number of subjects: 210
Study: 2847578

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium aerosol (2 inhalations; 2 mg/inhalation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31257987

Group type: EXPERIMENTAL
Intervention: Separate imputation by treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous imputation across all subjects
Number of subjects: 0
Study: 30270167

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 321

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 321
Study: 28213388

Group type: EXPERIMENTAL
Intervention: Dopamine donor pretreatment (4 µg/kg per minute continuous infusion)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control group (no dopamine infusion)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Dopamine donor pretreatment with infusion time of 7.1 hours
Number of subjects: 487
Study: 24951103

Group type: COMPARATOR
Intervention: Atacicept 75 mg
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 23391369

Group type: EXPERIMENTAL
Intervention: AZD9668 (150 mg single dose, 70 mg twice daily multiple doses)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: AZD9668
Number of subjects: 125
Study: 22043122

Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (eAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Number of subjects: 0
Study: 19117833

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation (100,000 IU bimonthly and 1 g/day calcium)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 17674917

Group type: EXPERIMENTAL
Intervention: Combined 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) with silicone oil
Number of subjects: 64

Group type: COMPARATOR
Intervention: Silicone oil without adjunctive medication (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combined 5-FU and LMWH with silicone oil
Number of subjects: 64
Study: 14724665

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day plus metoprolol 25 mg/day (group M)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sibutramine 10 mg/day plus placebo (group P)
Number of subjects: 57
Study: 11291370

Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention consisting of group discussions, outreach, and educational campaigns over 16 months.
Number of subjects: 2747
Study: 9278651

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg once daily, beginning 2 hours before surgery
Number of subjects: 631

Group type: COMPARATOR
Intervention: Unfractionated low-dose heparin, three times daily
Number of subjects: 631
Study: 8314960

Group type: EXPERIMENTAL
Intervention: 1.0 ng/ml EGF
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: 10.0 ng/ml EGF
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control (no EGF)
Number of subjects: 262
Study: 3578401

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive preparations (seven types)
Number of subjects: 10
Study: 28703491

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) plus two N(t)RTIs
Number of subjects: 238

Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (PI/r)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 238
Study: 26261074

Group type: COMPARATOR
Intervention: 200 U BTX‐A intradetrusor injections excluding the trigone (Control group)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 160 U intradetrusor and 40 U intratrigonal injections (Experimental group)
Number of subjects: 91
Study: 25335244

Group type: EXPERIMENTAL
Intervention: Acupuncture plus electric stimulation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Electric stimulation
Number of subjects: 74
Study: 23439172

Group type: EXPERIMENTAL
Intervention: Accu-Chek SmartPix information management system (IMS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Handwritten logbooks
Number of subjects: 25
Study: 20184578

Group type: EXPERIMENTAL
Intervention: Screening participants (PSA testing)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Non-participants (no PSA testing)
Number of subjects: 1000
Study: 19138485

Group type: EXPERIMENTAL
Intervention: Scarf osteotomy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Chevron osteotomy
Number of subjects: 115
Study: 16634976

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lack of social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate or large amounts of stress
Number of subjects: 0
Study: 12864879

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ramipril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blocker (DHP-CCB, amlodipine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker (metoprolol)
Number of subjects: 0
Study: 11472003

Group type: EXPERIMENTAL
Intervention: Sequential mode ablation technique
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Randomized mode ablation technique
Number of subjects: 58

Group type: COMPARATOR
Intervention: PMMA test plates
Number of subjects: 58
Study: 9258527

Group type: EXPERIMENTAL
Intervention: Influenza split vaccine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Influenza split vaccine + Pneumococcal 23-valent vaccine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Pneumococcal 23-valent vaccine (administered simultaneously with influenza vaccine)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (Influenza vaccine alone)
Number of subjects: 124
Study: 7943888

Group type: EXPERIMENTAL
Intervention: Film-forming preparation 'Lifusol' for catheter fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard catheter fixation with plaster
Number of subjects: 0
Study: 2945783

Group type: EXPERIMENTAL
Intervention: Synthetic human atrial natriuretic peptide (i.v. bolus of 25 micrograms followed by a 6‐hour infusion of 25 micrograms/hr)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Synthetic human atrial natriuretic peptide (i.v. bolus of 175 micrograms followed by a 6‐hour infusion of 100 micrograms/hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Angiotensin II (5, 10, 20 ng/kg/min)
Number of subjects: 6